CA2344690C - Fructosamine-oxydase: antagonistes et inhibiteurs - Google Patents

Fructosamine-oxydase: antagonistes et inhibiteurs Download PDF

Info

Publication number
CA2344690C
CA2344690C CA2344690A CA2344690A CA2344690C CA 2344690 C CA2344690 C CA 2344690C CA 2344690 A CA2344690 A CA 2344690A CA 2344690 A CA2344690 A CA 2344690A CA 2344690 C CA2344690 C CA 2344690C
Authority
CA
Canada
Prior art keywords
triene
diabetes
human
patient
long
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2344690A
Other languages
English (en)
Other versions
CA2344690A1 (fr
Inventor
John Richard Baker
Garth James Smith Cooper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Protemix Corp Ltd
Original Assignee
Protemix Corp Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protemix Corp Ltd filed Critical Protemix Corp Ltd
Priority claimed from PCT/NZ1999/000161 external-priority patent/WO2000018392A1/fr
Publication of CA2344690A1 publication Critical patent/CA2344690A1/fr
Application granted granted Critical
Publication of CA2344690C publication Critical patent/CA2344690C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)

Abstract

Cette invention se rapporte à des procédés servant à réduire les conséquences des dommages macrovasculaires et microvasculaires chez un patient diabétique, en recourant à l'inhibition et/ou l'antagonisme de la fructosamine-oxydase chez ce patient. Cette inhibition et/ou cet antagonisme peuvent impliquer l'utilisation d'agents de chélation au cuivre, d'analogues substrats ou de composés hydrazine.
CA2344690A 1998-09-25 1999-09-24 Fructosamine-oxydase: antagonistes et inhibiteurs Expired - Fee Related CA2344690C (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
NZ332079 1998-09-19
NZ332084 1998-09-25
NZ33208498 1998-09-25
NZ33207998 1998-09-28
NZ334471 1999-03-03
NZ33447199 1999-03-03
NZ33704299 1999-08-03
NZ337042 1999-08-09
PCT/NZ1999/000161 WO2000018392A1 (fr) 1998-09-25 1999-09-24 Fructosamine-oxydase: antagonistes et inhibiteurs

Publications (2)

Publication Number Publication Date
CA2344690A1 CA2344690A1 (fr) 2000-04-06
CA2344690C true CA2344690C (fr) 2011-03-22

Family

ID=27484372

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2344690A Expired - Fee Related CA2344690C (fr) 1998-09-25 1999-09-24 Fructosamine-oxydase: antagonistes et inhibiteurs

Country Status (6)

Country Link
JP (1) JP2003521453A (fr)
AU (1) AU772026B2 (fr)
CA (1) CA2344690C (fr)
DK (1) DK1115389T3 (fr)
ES (1) ES2461195T3 (fr)
PT (1) PT1115389E (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017049529A1 (fr) * 2015-09-24 2017-03-30 Innolife Co., Ltd. Composition pharmaceutique comprenant une tétramine de chélation de cuivre et utilisation de celle-ci
WO2023276786A1 (fr) * 2021-06-30 2023-01-05 株式会社村田製作所 Chélateur de cuivre, agent anticancéreux et agent prophylactique ou thérapeutique pour la maladie de wilson

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0321863A (ja) * 1989-06-19 1991-01-30 Shimadzu Corp トリエチレンテトラミン類分析法及びその装置

Also Published As

Publication number Publication date
CA2344690A1 (fr) 2000-04-06
AU772026B2 (en) 2004-04-08
DK1115389T3 (da) 2014-05-12
PT1115389E (pt) 2014-05-09
ES2461195T3 (es) 2014-05-19
JP2003521453A (ja) 2003-07-15
AU5887199A (en) 2000-04-17

Similar Documents

Publication Publication Date Title
EP1115389B1 (fr) Fructosamine-oxydase: antagonistes et inhibiteurs
Baxter et al. Elevation of γ-aminobutyric acid in brain: selective inhibition of γ-aminobutyric-α-ketoglutaric acid transaminase
Solem et al. Disruption of mitochondrial calcium homeostasis following chronic doxorubicin administration
Gassó et al. Effects of S-adenosylmethionine on lipid peroxidation and liver fibrogenesis in carbon tetrachloride-induced cirrhosis
CA2279428C (fr) Composes et procedes concernant l&#39;utilisation d&#39;agents therapeutiques dans la prevention de complications diabetiques
AU2004298393A1 (en) Copper antagonist compounds
CA2245836A1 (fr) Utilisation de composes deprenyliques pour maintenir ou permettre de retrouver les fonctions des cellules nerveuses, ou pour eviter la perte de ces fonctions
US20100160428A1 (en) Treatment of mitochondria-related diseases and improvement of age-related metabolic deficits
CA2344690C (fr) Fructosamine-oxydase: antagonistes et inhibiteurs
JP5349722B2 (ja) 金属結合化合物およびその使用方法
NZ539272A (en) Using an antagonist or an inhibitor of Fructosamine oxidase to reduce minimising the effects of macrovascular and microvascular damage in a diabetic patient
AU2004200539A1 (en) Fructosamine oxidase: Antagonists and inhibitors
WO2000066101A2 (fr) Procede permettant d&#39;inhiber la formation d&#39;un produit de glycation
CA2361575A1 (fr) Formulations a base de l-arginine utilisees dans le traitement de maladies, et leurs procedes d&#39;utilisation
JP2002528419A (ja) 糖尿病性合併症に対する化合物およびその治療的使用
CA2455805C (fr) Composes et procedes concernant l&#39;utilisation d&#39;agents therapeutiques dans la prevention de complications diabetiques
EP1671630A2 (fr) Formulations basées sur l-arginine pour le traitment des maladies et méthodes utilisants les memes
Zahlten Hepatic porphyrias and heme metabolism
JPH02212424A (ja) 肝障害抑制剤
GB2245491A (en) Inhibition of metabolic oxalate formation
AU2016203655A1 (en) Treatment of mitochondria-related diseases and improvement of age-related metabolic deficits

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed